|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:active_metabolite_of
|
gptkb:irinotecan
|
|
gptkbp:CASNumber
|
86639-52-3
|
|
gptkbp:category
|
alkaloid
antineoplastic agent
lactone
|
|
gptkbp:derivedFrom
|
gptkb:irinotecan
|
|
gptkbp:drugClass
|
topoisomerase inhibitor
|
|
gptkbp:hasInChIKey
|
QBPZKZZCQLOAIF-VCHYOVAHSA-N
|
|
gptkbp:hasMolecularFormula
|
C22H20N2O5
|
|
gptkbp:hasSMILES
|
CC[C@H]1C2=C(C=CC(=C2)O)C3=C4C(=O)N(C)C(=O)C4=CC5=C3C1=CC=C5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SN-38
|
|
gptkbp:IUPACName
|
(20S)-7-ethyl-10-hydroxycamptothecin
|
|
gptkbp:mechanismOfAction
|
inhibits topoisomerase I
|
|
gptkbp:metabolism
|
gptkb:UGT1A1
|
|
gptkbp:molecularWeight
|
392.41 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL190836
104842
CHEBI:9027
|
|
gptkbp:relatedTo
|
gptkb:camptothecin
|
|
gptkbp:routeOfAdministration
|
intravenous (as irinotecan prodrug)
|
|
gptkbp:solubility
|
poorly soluble in water
|
|
gptkbp:toxicity
|
diarrhea
myelosuppression
|
|
gptkbp:UNII
|
2Y1W8T8A7X
|
|
gptkbp:used_in
|
cancer chemotherapy
|
|
gptkbp:bfsParent
|
gptkb:irinotecan
gptkb:PEN-866
gptkb:Camptothecin
gptkb:Trodelvy
|
|
gptkbp:bfsLayer
|
7
|